Alison Goate
Alison Mary Goate is the Jean C. and James W. Crystal Professor and Chair of the Department of Genetics and Genomic Sciences and Director of the Loeb Center for Alzheimer's Disease at Icahn [School of Medicine at Mount Sinai]. She was previously professor of genetics in psychiatry, professor of genetics, and professor of neurology at Washington [University School of Medicine].
The Goate Lab studies the genetics and molecular bases of Alzheimer's disease, frontotemporal dementia, and alcoholism.
Education and early career
After receiving her undergraduate degree in biochemistry at the University of Bristol and her graduate training at Oxford University, Goate studied under Professors Theodore Puck, Professor Louis Lim and Dr. John Hardy. She received a Royal Society University Research Fellowship to conduct research at St. Mary's Hospital Medical School in London.Awards and affiliations
She has received the Potamkin Prize from the American Academy of Neurology, the Zenith Award from the Alzheimer's Association, Senior Investigator Award from the Metropolitan Life Foundation, the St. Louis Academy of Science Innovation Award, Carl and Gerty Cori Faculty Achievement Award at Washington University in St. Louis, and a Lifetime Achievement Award from the Alzheimer's Association. She is a fellow of the American Association for the Advancement of Science. She also serves on the faculty of the Hope Center for Neurological Disorders and is an elected member of the National Academy of Medicine. Goate received the Rainwater Prize for Innovation in Neurodegeneration from the Rainwater Charitable Foundation in 2022. Goate was the first female to be awarded the Piepenbrock-DZNE Prize for Neurodegenerative disease research in 2023.Research
Goate's research centers on the genetics of Alzheimer's disease and related dementias that led to the development of animal and cellular models and the development of anti-amyloid and anti-tau therapies. She has been the principal investigator on four grants and has co-invented and awarded six patents.Patents
- APP770 mutant in alzheimer's disease,.
- Mutant S182 genes,.
- Method for elucidation and detection of polymorphisms, splice variants, and proximal coding mutations using intronic sequences of the Alzheimer's S182 gene,.
- Transgenic mouse expressing an APP-FAD DNA sequence,.
- Pathogenic Tau mutations,.
- Markers for addiction,.
Grants
| Funding Source, Project Title & Number | Role in Project | Dates | Direct Costs |
| NIH/NIA/Columbia University National Institute on Aging Alzheimer's Disease Family-Based Study U24AG056270 | Subaward PI | 8/1/2022 - 4/30/2027 | $151,653 |
| NIH/NIA Neuroprotective Signaling and Transcriptional Pathways in Microglia Associated with Alzheimer's Disease R01AG072489 | MPI | 2/1/2022 - 11/30/2026 | $5,972,363 |
| NIH/NINDS Uncovering the Genetic Mechanisms of the Chromosome 17q21.31 Tau haplotype on Neurodegeneration Risk in FTD and PSP U54NS123746 | MPI | 9/1/2021 - 8/31/2026 | $9,278,441 |
| The JPB Foundation Integrative approaches to the identification of AD risk genes and novel therapeutics 2023-4265 | Principal Investigator | 9/1/2023 - 8/31/2026 | $2,250,000 |
| NIH/NIA/Mayo Clinic Biology and Pathobiology of ApoE in Aging and Alzheimer's Disease U19AG069701 | Subaward PI | 6/1/2021 - 5/31/2026 | $1,885,527 |
| Cure Alzheimer's Foundation Investigating MEF2C transcription factor as therapeutic targets to reprogram pathological microglial states in Alzheimer's disease | Principal Investigator | 1/14/2024 - 1/13/2026 | $201,250 |
| Rainwater Charitable Foundation Using unbiased proteomics to validate iPSC models of FTD-MAPT and discover novel biomarkers | MPI | 8/1/2023 - 7/31/2025 | $200,000 |
| NIH/NIA/Massachusetts Institute of Technology Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease U01AG066757 | Subaward PI | 5/15/2020 - 4/30/2025 | $1,364,375 |
| NIH/NIA/Banner Health APOE in the Predisposition to, Protection from and Prevention of Alzheimer's Disease R01AG069453 | Subaward PI | 7/1/2020 - 3/31/2025 | $71,390 |
| NIH/NIA/University of Pennsylvania Alzheimer's Disease Genetics Consortium U01AG032984 | Subaward PI | 3/6/2020 - 8/31/2024 | $1,021,752 |
| NIH/NINDS/University of Miami Reducing Disparities in Dementia and VCID Outcomes in a Multicultural Rural Population R01NS101483 | Subaward PI | 4/15/2020 - 3/31/2025 | $78,593 |
| NIH/NIAAA/SUNY Collaborative Study on the Genetics of Alcoholism U10AA008401 | Subaward PI | 9/1/2019 - 8/31/2024 | $2,175,426 |
| M.D. Anderson Understanding the mechanism of MS4A-dependent AD risk AGR-13139 | Principal Investigator | 8/7/2017 - 8/31/2024 | $3,562,500 |
| NIH/NIA Genomic Approach to Identification of Microglial Networks Involved in Alzheimer's Disease Risk U01AG058635 | Principal Investigator | 8/1/2018 - 7/31/2024 | $4,799,685 |
| NIH/NIA/Washington University DIAN Genetics Core U19AG032438 | Subaward PI and Core Leader | 7/1/2019 - 6/30/2024 | $651,291 |
| Rainwater Charitable Foundation Investigating rare and common mechanisms underlying tauopathy risk | Principal Investigator | 11/1/2022 - 4/30/2024 | $230,000 |
Publications
Semantic Scholar lists 483 publications, 22,943 citations and 1,808 influential citations of Goate's peer-reviewed and original contribution as of 2019.Partial list:
- Cited by 5017 as of October 18, 2019.
- Cited by 2274 as of October 18, 2019.
- Cited by 793 as of October 18, 2019
- Cited by 604 as of October 18, 2019.
- Cited by 419 as of October 18, 2019
- Cited by 275 as of October 18, 2019.
- .
- .
- .
- .
- .
- .
- .